In the planned how well it works study, a prospective randomly assigned controlled trial will be conducted to investigate the extent to which a multimodal stress reduction and lifestyle modification program can be reflected in patients with irritable bowel syndrome (IBS) within the framework of a clinical study. For this purpose, 118 patients with IBS will be enrolled in a clinical study.
Official registry: https://clinicaltrials.gov/study/NCT06145022 · Universität Duisburg-Essen · enrollment listed as 118
This study does not use the classic phase 1–4 drug ladder. It may be a device, a behavior program, a surgery timing study, or an early feasibility test.
Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
If you join, the listed intervention(s) are lifestyle modification, or waitlist control group. The registry lists allocation as randomized. In the planned how well it works study, a prospective randomly assigned controlled trial will be conducted to investigate the extent to which a multimodal stress reduction and lifestyle modification program can be reflected in patients with irritable bowel syndrome (IBS) within the framework of a clinical study.
They plan to enroll about 118 people at Bamberg. Taking part typically means following a program (exercise, therapy, diet, or an app) plus check-ins.
Effect of a Stress Reduction and Lifestyle Modification Programme on the Quality of Life of Irritable Bowel Syndrome Patients (MBM IBS)
Interventions: lifestyle modification, waitlist control group
Primary outcome (registry wording): Severity of IBS symptoms by IBS-SSS
Sandra Utz, PhD
sandra.utz@sozialstiftung-bamberg.de
Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.
Aim: More insight in pathogenesis of IBS and IBD. Samples are collected in context of an European research project.
NCT02421705 · Official ClinicalTrials.gov record · KU Leuven
Gastrointestinal (GI) infection with Campylobacter causes inflammation in the bowel and can change bacteria in the gut. Certain individuals with Campylobacter infection are also known to develop chronic bowel problems such as Irritable Bowel Syndrome (IBS).
NCT03223077 · Official ClinicalTrials.gov record · Mayo Clinic
This study will assess the how well it works of two active treatments with TEA and a chemical neuromodulator (escitalopram aka Lexapro) versus a sham comparator or control group on abdominal pain.
NCT05519683 · Official ClinicalTrials.gov record · University of Michigan
The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.
Not a traditional drug phase. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.
How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary